Stramsen Biotech Inc. Secures $25M to Fast-Track Breakthrough Plant-Based Therapeutics

Stramsen Biotech, Inc., a pioneering Texas-based biopharmaceutical company, is excited to announce a recent funding milestone of US$25,000,000. Incorporated in Delaware in November 2020 and headquartered in Houston, the company is dedicated to using a natural, plant-based approach to revolutionize medicine for patients worldwide. With access to a comprehensive database of over 8,000 medicinal plants, Stramsen Biotech is uniquely positioned to explore and harness nature’s potential in the treatment of a broad spectrum of infectious and noninfectious diseases. The fresh capital injection will accelerate the development and clinical trials of several innovative therapeutic candidates, including SBX 1052 for managing prostate gland enlargement, SBX1968 and SBX 2021 targeting various forms of cancer, and SBX 2022 aimed at blood cancer. In addition, the funding will bolster progress on SBX 2023, intended to treat peripheral neuropathic disorders; SBX 2000, developed for cardiovascular disease management; and SBX 1977, a versatile wound healing drug with robust antibacterial and cell proliferation properties. The pipeline also features promising treatments for HIV, diabetes, and kidney infections, as well as therapies that address joint and bone ailments. With over 40% of global medicinal products derived from plant sources, the company’s research strategy emphasizes rigorous clinical testing and innovative natural solutions to complex health challenges. These financial resources are set to expand Stramsen Biotech’s research capabilities, streamline product development, and ultimately transform the lives of patients facing challenges from diseases ranging from COVID-19 to chronic conditions like diabetes and cardiovascular diseases. This funding round marks a significant step forward in the company’s mission to deliver groundbreaking, plant-derived therapies to the global healthcare market.